ReviewCancer journal (Sudbury, Mass.)
Adjuvant therapy for melanoma.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Recent Research Trends against Skin Carcinoma - An Overview.Current pharmaceutical design · 2024Review
- Mannose-functionalization of reconstituted high-density lipoprotein nanoparticles improves payload delivery and enhances M2-to-M1 phenotype reprogramming of RAW 264.7 macrophages polarized by B16-F10 melanoma cells.Frontiers in drug delivery · 2023Article
- Charting roadmaps towards novel and safe synergistic immunotherapy combinations.Nature cancer · 2022Review
- MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.Frontiers in oncology · 2020Review
- A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer.Biophysical reviews · 2019Review
- Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report.Journal of medical case reports · 2016Article
- Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.Melanoma management · 2016Review
- Para-Phenylenediamine Induces Apoptotic Death of Melanoma Cells and Reduces Melanoma Tumour Growth in Mice.Biochemistry research international · 2016Article
- Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways.International journal of molecular sciences · 2015Article
- Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.JAMA oncology · 2015Article
- Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma.Melanoma management · 2015Review
- Primary malignant melanoma of the breast: A case report and review of the literature.Oncology letters · 2014Article
- BRAF and beyond: Tailoring strategies for the individual melanoma patient.Journal of carcinogenesis · 2014Review
- Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.Methods in molecular biology (Clifton, N.J.) · 2014Review
- Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach.Wiener medizinische Wochenschrift (1946) · 2013Review
- Article
- Metastatic melanoma to the brain: surgery and radiation is still the standard of care.Current treatment options in oncology · 2013Article
- Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.Journal of virology · 2013Article
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.Nature genetics · 2013Article
- Immunoregulatory molecules are master regulators of inflammation during the immune response.FEBS letters · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Estimates from the U.S. Surveillance, Epidemiology, and End Results registry suggest that melanoma incidence will reach 70,230 cases in 2011, of whom 8790 will die. The rising incidence and predilection for young individuals makes this tumor a leading source of lost productive years in the society.High-dose interferon-α-2b is the only agent approved for adjuvant therapy for melanoma; the improvement in relapse-free survival has been observed across nearly all published studies and meta-analyses. However, toxicity affects compliance, and current research is focusing on biomarkers that may allow selection of patients with greater likelihood of response and exploring new agents either singly or in combination that may improve on the benefit of interferon.In this article, we review the data for the adjuvant therapy for malignant melanoma--focusing on the results obtained with various regimens testing the several formulations of interferon-α2 and the adjuvant studies of vaccines and radiotherapy. Recent advances in the treatment of metastatic disease have established a role for CTLA-4 blockade and BRAF-inhibition, raising hopes that these agents may have a role in the adjuvant setting. At present, several trials investigating combinations of novel agents with existing immunomodulators are underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.